Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
By M. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, E. Simonsen, G. Stuart, S. Kaye, I. Vergote, R. Blom and 18 more. Journal of the National Cancer Institute, 2000
1,009 citations recorded by the source corpus.
Subfields: Oncology, Public Health, Environmental and Occupational Health, Reproductive Medicine
View Paper: https://www.semanticscholar.org/paper/3eeee034b2069f6465fe0c7543d8031b818f23d8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Reproductive Medicine
Citations in the corpus
- Ovarian cancer: strategies for overcoming resistance to chemotherapy (2003, background): “Two studies showed a significant benefit for paclitaxel–cisplatin combination chemotherapy compared with cyclophosphamide–cisplatin chemotherapy, and this led to its widespread adoption as a standard first-line treatment in ovarian cance”
- Cyclophosphamide and cancer: golden anniversary (2009, background): “Ovarian cancer In two prospective, randomized trials”
- Recent Progress in the Diagnosis and Treatment of Ovarian Cancer (2011, methodology): “mide and cisplatin regimen was confirmed in a European Organization for Research and Treatment of Cancer (EORTC) study.(71) The latter trial used 3-hour paclitaxel with cisplatin and demonstrated an increased incidence of high-grade neurotoxicity.”
- A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. (2003, methodology): “The results of our study support the findings of other clinical trials (5, 6 ,27) of paclitaxel-plus-platinum chemotherapy in patients with ovarian cancer.”